Fate Therapeutics Inc (FATE): Operating Income

Annual figures by period end, from SEC filings.

-$147.70M

Year ended 2025-12-31

-$133.59M

Trailing 12 months to 2026-06-30

2011-12-31 Operating Income (USD) 2025-12-31

Period ended	Operating Income	Change YoY	Source filing
2025-12-31	-$147.70M	n/m	2026-02-26, From 2025-01-01
2024-12-31	-$210.28M	n/m	2026-02-26, From 2024-01-01
2023-12-31	-$190.51M	n/m	2025-03-05, From 2023-01-01
2022-12-31	-$308.39M	n/m	2024-02-26, From 2022-01-01
2021-12-31	-$216.99M	n/m	2023-02-28, From 2021-01-01
2020-12-31	-$128.09M	n/m	2023-02-28, From 2020-01-01
2019-12-31	-$100.73M	n/m	2022-02-28, From 2019-01-01
2018-12-31	-$67.09M	n/m	2021-02-24, From 2018-01-01
2017-12-31	-$42.12M	n/m	2020-03-02, From 2017-01-01
2016-12-31	-$31.96M	n/m	2019-03-05, From 2016-01-01
2015-12-31	-$27.78M	n/m	2018-03-05, From 2015-01-01
2014-12-31	-$24.90M	n/m	2017-03-16, From 2014-01-01
2013-12-31	-$17.68M	n/m	2016-03-03, From 2013-01-01
2012-12-31	-$13.56M	n/m	2015-03-12, From 2012-01-01
2011-12-31	-$13.29M	n/a	2014-03-17, From 2011-01-01

Operating Income at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Income	Change YoY
Fate Therapeutics Inc (FATE)	2025-12-31	-$147.70M	n/m
DBV Technologies S.A. (DBVT)	2025-12-31	-$147.06M	n/m
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	-$5.39M	n/m
Curis Inc (CRIS)	2025-12-31	-$5.71M	n/m
Prime Medicine, Inc. (PRME)	2025-12-31	-$208.35M	n/m
Taysha Gene Therapies, Inc. (TSHA)	2025-12-31	-$110.50M	n/m
Ocugen, Inc. (OCGN)	2025-12-31	-$62.92M	n/m
Alpha Cognition Inc. (ACOG)	2025-12-31	-$22.66M	n/m
TScan Therapeutics, Inc. (TCRX)	2025-12-31	-$135.81M	n/m

Compare FATE, DBVT, ZEOX, CRIS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗